Royalty Pharma (RPRX) Non Operating Investment Income (2020 - 2021)

Royalty Pharma (RPRX) posted Non Operating Investment Income of $11.8 million for Q3 2021, down 11.6% sequentially from $13.3 million in Q2 2021.

Royalty Pharma (RPRX) Non Operating Investment Income (2020 - 2021) Analysis & Trends

Royalty Pharma has reported Non Operating Investment Income for 2 years, with the latest figure at $11.8 million in Q3 2021.

Quarterly Non Operating Investment Income changed N/A year-over-year to $11.8 million in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $50.2 million (changed N/A YoY) and the FY2020 annual result came in at $20.6 million, changed N/A from the prior year.
Non Operating Investment Income eased to $11.8 million in Q3 2021 per RPRX's latest filing, from $13.3 million in the prior quarter.
Over five years, Non Operating Investment Income peaked at $20.6 million in Q4 2020 and troughed at $4.6 million in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non Operating Investment Income (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Roivant Sciences	26.20 Bn	26.20 Bn	1.16 Mn	36.64 Mn

Download Data